Research Trials
If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.955.2691, or email us at clinicaltrials@nebraskacancer.com.
-
Cancer Type:
-
Biomarker:
-
Phase:
-
Keyword:
-
VMT-a-NET
Phase 1/2a first in human study of VMTaNET Targeted Alpha Particle Therapy for advanced SSTR2 Positive Neuroendocrine TumorsCancer Type: Neuroendocrine, Theranostics
Lines of Therapy: 1
Biomarkers: SSTR2
Phase: 1
View Details on ClinicalTrials.gov
-
XL092-002 (STELLAR 002)
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)Cancer Type: Renal
Phase: 1b
View Details on ClinicalTrials.gov
-
SLC-391-102, Skylite
Phase 1b/2 study of SLC-391, an AXL inhibitor, in ccombination with pembrolizumab in subjects wiht advanced or meastatic NSCLCCancer Type: Lung NSCLC
Lines of Therapy: 3, 2, 1
Biomarkers: PD-L1+
Phase: 2
View Details on ClinicalTrials.gov
-
RYZ101-101
Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)Cancer Type: Lung SCLC
Lines of Therapy: 1
Biomarkers: SSTR+
Phase: 1
View Details on ClinicalTrials.gov
-
Teligene (TL-EGFR-2201)
A phase 2 study to evaluate the efficacy and safety of Sutetinib Maleate Capsule in locally advanced or metastatic NSCLCCancer Type: Lung NSCLC
Lines of Therapy: 2
Phase: 2
View Details on ClinicalTrials.gov
-
SIBYL, 06-MX-001, PLP-002043-R2
Observational study of therapy response with liquid biopsy evaluation.Cancer Type: BREAST, Colorectal
Lines of Therapy: 2, 1
Phase: Observational
View Details on ClinicalTrials.gov
-
VM Oncology, VMO-01C
Open label, multidose, dose escalation study to investigate the safety, pharmokinetics, and pharmacodynamics of VMC 928 in subjects with solid tumors or lymphomaCancer Type: Solid tumor, Lymphoma
Biomarkers: TrkA
Phase: 1
View Details on ClinicalTrials.gov
-
TPX-0005-07
A Phase 1/2, Open-label, safety, tolerability, pharmacokinetics, and anti-tumor activity study of repotrectinib in pediatric and young adult subjects with advances or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterationsCancer Type: Solid tumor
Biomarkers: ALK, ROS1, NTRK1-3
Phase: 2
View Details on ClinicalTrials.gov
-
Teligene (SZCT-2020-06)
A Phase 2b study to evaluate the efficacy and safety of sutetinib maleate capsule in locally advanced or metastatic NSCLC (non-resistant uncommon EGFR mutations only, including L861Q, G719X, and/or S768I)Cancer Type: Lung NSCLC
Lines of Therapy: 2
Phase: 2b
View Details on ClinicalTrials.gov
-
RYZBIO-801
Phase 1/1b single arm, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic to identify and treat subjects with GPC3 positive unresectable hepatocellular carinoma (HCC)Cancer Type: hepatocellular, Theranostics
Biomarkers: GPC3
Phase: 1